Quantcast

Latest Prostate Stories

2014-09-30 08:32:22

Trelstar® one-, three-, and six-month dosing options now available TORONTO and LAUSANNE, Switzerland, September 30, 2014 /PRNewswire/ -- Trelstar(R) (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer,[1] is now available in a six-month dosing option (22.5 mg). The new dosing option eases the burden on patients, with a decreased number of injections and a low incidence of injection site pain, while providing...

2014-09-30 08:30:47

Prostate Cancer Canada grant aims to accelerate pace of discovery of novel therapies TORONTO, Sept. 30, 2014 /CNW/ - Prostate Cancer Canada is in a race to give the approximately 24,000 Canadian men diagnosed with prostate cancer each year a better fighting chance. In response to the urgent need to increase the pace of discovery, Prostate Cancer Canada just awarded a Translation Acceleration Grant (TAG) to a team led by Dr. Paul Rennie of the Vancouver Prostate Centre and the...

2014-09-29 16:25:57

Additional Tests to Demonstrate the Importance of Utilizing Multiple Biological Pathways to Provide Patients, Physicians with Confidence to Make Educated Treatment Decisions CAMBRIDGE, Mass., Sept. 29, 2014 /PRNewswire/ -- Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA(®) PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay. These tests...

2014-09-29 16:24:13

TORONTO, Sept. 29, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY -- Prostate Cancer Canada is in a race to give the approximately 24,000 Canadian men diagnosed with prostate cancer each year a better fighting chance. In response to the urgent need to increase the pace of discovery, Prostate Cancer Canada will be funding breakthrough research into a new generation of drugs that used alone or in combination with other therapies will...

2014-09-29 08:31:04

Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness REDWOOD CITY, Calif., Sept. 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University...

2014-09-29 08:29:46

Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress TORONTO, Sept. 29, 2014 /CNW/ - A final analysis of the Phase 3 COU-AA-302 trial presented at the European Society for Medical Oncology (ESMO) conference in Madrid, Spain showed that ZYTIGA(®) (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to...

2014-09-29 08:25:54

TORONTO, Sept. 29, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY -- Prostate Cancer Canada is in a race to give the approximately 24,000 Canadian men diagnosed with prostate cancer each year a better fighting chance. In response to the urgent need to increase the pace of discovery, Prostate Cancer Canada will be funding breakthrough research into a new generation of drugs that used alone or in combination with other therapies will...

2014-09-26 23:01:32

New genetic links to prostate cancer can identify men at higher risk and may lead to targeted screening, according to researchers at CPIC and colleagues. Fremont, CA (PRWEB) September 26, 2014 A major international study has identified 23 new genetic variants that are associated with an increased risk of developing prostate cancer, according to researchers at the Cancer Prevention Institute of California (CPIC) and their colleagues. With this new study, there are now 100 genetic variants...

2014-09-25 08:27:17

SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostic laboratory testing. The agreement includes GenomeDx Biosciences' participation in the MultiPlan Network, expanding access to the Decipher(®) Prostate Cancer Classifier to health plan members who access the more than 500,000 providers participating in the MultiPlan Network. The Decipher prostate cancer classifier directly...

2014-09-24 23:08:39

MarketOptimizer.org adds “Spain Non-Vascular Stents Market Outlook to 2020” to its store. The data in the report is derived from dynamic market forecast models. Dallas, Texas (PRWEB) September 24, 2014 “Spain Non-Vascular Stents Market Outlook to 2020″, provides key market data on the Spain Non-Vascular Stents market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments – Biliary Stents (Plastic...


Latest Prostate Reference Libraries

Prostate
2013-03-04 15:21:55

The male prostate gland acts as an exocrine gland in the male reproductive system. It is a firm, partly muscular, chestnut sized gland near the neck of the urethra in males. Formation and Orientation The prostate is usually formed within the ninth week of the embryonic stage in reproductive development. The prostate can be separated into either “lobes” or “zones”. When looking at a prostate divided into zones, there are four distinct regions. The first zone is the Peripheral...

More Articles (1 articles) »
Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related